Phase III Randomized Adjuvant Study Of Pembrolizumab In Muscle Invasive And Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation Read more
Phase II Study Of Front Line Therapy With Nivolumab And Salvage Nivolumab + Ipilimumab In Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260 Read more
